ViiV Two-Drug HIV Pill Juluca Close To Europe Okay
Executive Summary
The likely EMA approval of Juluca challenges the traditional HIV treatment paradigm of a three-drug regimen, with the single tablet, two-drug regimen offering the same efficacy as well as reduced toxicity and greater convenience.
You may also be interested in...
Janssen And ViiV: Giving HIV/AIDS Patients Options Is Key
With EU submissions for once-monthly long-acting anti-HIV antivirals in hand, Janssen and ViiV appear to have set their sights on providing patients with more options.
SWORD Data Sharpen Commercial Appetite For ViiV’s Juluca, But Is It Too Little Too Late?
ViiV Healthcare has published results from the first long-term Phase III study for switching from a three-drug combination, to an oral two-drug combination. It disproves resistance and safety fears that have hampered prescriber comfort, however, it may have to dampen its sales ambitions when ViiV’s soon-to-be-approved combo Tivicay/Epivir comes to market.
ViiV Boosted By Early GEMINI Data, But More Details Wanted
ViiV Healthcare has positive early pivotal data for its second two-drug regimen for HIV, but more reassurance is needed on the relative rates of virologic suppression in patients with low and high viral loads, as well as on the long-term risk of virologic failure. The combination should help form ViiV's defense against rival Gilead and its new triple combination Biktarvy.